Tempest Therapeutics Inc. (TPST)
NASDAQ: TPST
· Real-Time Price · USD
7.08
-0.07 (-0.98%)
At close: Jun 26, 2025, 3:59 PM
-0.98% (1D)
| Bid | 6.88 |
| Market Cap | 28.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.8M |
| EPS (ttm) | -18.04 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | -0.68 |
| Analyst | Hold |
| Ask | 7.5 |
| Volume | 54,243 |
| Avg. Volume (20D) | 122,732 |
| Open | 7.04 |
| Previous Close | 7.15 |
| Day's Range | 7.04 - 7.13 |
| 52-Week Range | 5.36 - 30.03 |
| Beta | -2.33 |
About TPST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TPST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TPST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-15.88%
Tempest Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
3 weeks ago
+15.07%
Tempest Therapeutics shares are trading higher after the company announced it received orphan drug designation from the EMA for its amezalpat for the treatment of patients with hepatocellular carcinoma
